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1. ABSTRACT  
Purpose: To analyse the occurrence and cost of dry eye disease in Spain throughout 
recent years. 
Methods: A cross-sectional analysis based on anonymised data recorded from 1997 to 
2015 from public and private hospitals and healthcare centres from an insurance claims 
database with a total of 36,081 patients eligible for the study after duplicate elimination. 
Selection from the database by means of the International statistical classification of 
diseases and related health problems (9th revision) associated with Dry eye syndrome 
codes. Number of cases, total cost, mean cost per patient, annual number of patients, 
annual number of visits, patient characteristics, hospitalizations and comorbidities. 
Results: Only 12% of the patients who presented dry eye diseased were male, whereas 
the mean age was approximately 65 across all study groups. Both the annual number of 
patients and visits have increased exponentially since 1997 raising from 1,079 and 1,342 
to 3,097 and 5,922 patients and visits, respectively. Hospitalizations had a length of stay 
of 9.6 [SD±11.6] days where more than 65% were due to emergency admissions and 92% 
were discharged home. Total costs were found to increase from 3.7M€ to 30.3M€ during 
the studied time period and an increase was also observed concerning the mean cost per 
patient and per visit.  
Conclusions: Estimating that disease incidence is likely to increase due to the influence 
of modern day work place, it is important to take into account the high economic burden 
and large decrease in quality of life in regards to Spanish society and health policies.  
 
KEYWORDS 
Dry eye disease; economic impact study; claims database analysis; Spain.  
2. INTRODUCTION 
The currently established definition of dry eye disease (DED) describes it as a chronic 
and progressive multifactorial disorder characterized by a tear film and ocular surface 
alteration [1-3]. The cause of this phenomenon may be either tear deficiency or excessive 
evaporation of the lacrimal fluid, which may cause ocular discomfort, irritation, ocular 
fatigue, visual disturbance and tear film instability, ultimately leading to potential 
damage to the ocular surface. An increased osmolarity of the tear film and inflammation 
of the ocular surface can also be observed. All these factors contribute to a noticeable 
decrease in quality of life (QoL) [4]. 
Risk factors associated to DED include adverse environmental conditions such as lack of 
humidity, chemicals and atmospheric dust, prolonged computer and electronic device 
usage, contact lenses and ionizing radiation. It is therefore very closely associated to 
modern day offices and will only lead to an incidence increase throughout the years [2-5]. 
According to the cause of tear film defect, DED can be subcategorized into Sjögren 
syndrome (SS) DED and non-SS DED in the case of tear deficiency [6]. In regards to 
excess evaporation, the most common cause is meibomian gland dysfunction (MGD) [7]. 
The importance of knowing the number of cases, cost and epidemiology of the disease  
lies in the fact that DED is among the most frequently diagnosed ophthalmologic diseases 
and leads to a large economic and social burden by means of a decrease in patient QoL 
[2]. The impact is associated to both the patients and the healthcare system due to direct 
and indirect costs concerning medical visits, therapies, surgeries, the frequent use of eye 
drops and a decrease in professional productivity caused by a reduced QoL [7]. 
Many studies indicate that the occurrence of the disease increases with age and is more 
commonly diagnosed in women [1-5,8]. However, reports disagree when it comes to the 
prevalence range. While some imply DED affects from 5% to 33% of the worldwide 
population [7], others argue it can reach as much as 50% or as little as 0.02% [1,9]. A 
second fact that most publications acknowledge is that DED has a higher prevalence in 
Asiatic or Far Eastern countries relative to Europe or the US. The most common 
hypothesis being, the existence of a genomic factor associated to the disease [5,10]. 
Because of its close association to the work environment, disease occurrence is expected 
to increase during the following years generating more costs for both health service and 
patients. 
There is a clear lack of research regarding the number of cases and cost of DED, however 
it is apparent that the economic burden of the disease is not negligible.  
The most recent and seemingly the only publication regarding dry eye disease occurrence 
in Spain is from 2009 [8]. The article discusses the epidemiology of DED in over 40 year 
old patients in the north-western region of the country exclusively. A second publication 
by the same authors (2012) evaluates the occurrence of MGD, a subcategory of DED, in 
the same region [11]. 
A comparative study discusses the occurrence and annual costs of DED in France, 
Germany, Italy, Spain, Sweden and the United Kingdom amongst patients managed by 
ophthalmologists [9]. However, there are no other references available regarding DED-
related costs. Consequently, there is an obvious need to update the available information 
regarding DED.  
Herein we study the number of cases and cost of DED in Spain throughout recent years 
by means of the analysis of data obtained from an insurance claims databases containing 
private and public hospital and healthcare centre records concerning the whole territory. 
 
3. METHODS 
A total of 62,050 records of patients with DED were obtained from the database by 
means of the appropriate International statistical classification of diseases and related 
health problems, 9th revision (ICD9) code. The national hospitalisation database contains 
information regarding records generated from both private and public hospitals and 
health centres available since 1997 up to 2015, on account of recent reports not yet being 
published. Parameters such as health centres and medical history identifiers have been re-
coded in order to maintain records anonymised.  
After discarding duplicate data, corresponding to patients that have been visited more 
than once, the final analysed data consisted of 36,081 records, which are the number of 
patients that have developed the pathology at some point in time. 
Ethics Committee ruled that approval was not required for this study. 
Data analysis 
Data presentation and analysis are generally descriptive, having not tested any specific 
hypothesis. Data is presented as mean values ± standard deviation (SD) and as 
percentages. 
The number of visits and number of patients per year has been calculated. Patient 
characteristics and most common comorbidities have also been studied.  
4. RESULTS 
In order to obtain patients records for DED five ICD9 codes were used. The codes that 
were considered corresponded to vitamin A deficiency with xerophthalmic scars of 
cornea (ICD9 264.6), Xerophthalmia due to vitamin A deficiency (ICD9 264.7), 
Keratoconjunctivitis sicca not specified as Sjögren's (ICD9 370.33), Dry eye syndrome 
(ICD9 375.15) and Keratoconjunctivitis sicca Sjögren's disease (ICD9 710.2). All the 
above diseases fall under the scope of DED.  
Out of a total of 36,081 patients around 4,308 (12%) were males and 31,769 (88%) 
female (Table 1). Both sex groups had similar means in regards to age, approximately 65 
years with a SD of 15.24 years concerning the male group and 15.06 years for the 
women.  
Table 1 Dry eye disease database patient characteristics 
     
 
Since records began, cases of patients with DED have shown an exponential growth 
throughout the years therefore, as expected, health service visits also show an annual 
increase (Table 2). This is partially explained by the chronic nature of the disease. 
 All patients Men Women Undetermined 







Age (years)     
 Mean 65.56 65.15 65.61 63.25 
 SD 15.24 16.48 15.06 11.32 
 Median 68 68 68 59 
 Range 0-105 0-98 0-105 55-80 
      
However, visits per year increase more abruptly as a result of an increment of patients 
that have been visited more than once or an increase of visits per patient. 
Hospitalizations have a mean duration of stay of 9.6 days, and 8,430 out of the recorded 
62,050 visits (13.6%) are readmissions (Table 3). Most hospital admissions, regarding 
both inpatient (day care) and outpatient hospitalisations (at least 1 night stay), are due to 
emergencies (65.5%) whereas 34.2% are scheduled. Regarding the nature of hospital 
discharges, patients are most frequently sent home (92.4%), a minimal portion of them 
are transferred to another hospital (1.9%) or are discharged voluntarily (0.2%).  
Table 2 Patients per year, visits per year and cost analysis related to dry eye disease 








1997 1,079 1,342 3,667,846 2,733 3,399 
1998 1,181 1,634 4,815,757 2,947 4,078 
1999 1,135 1,720 4,875,330 2,834 4,295 
2000 1,285 1,905 5,420,442 2,845 4,218 
2001 1,257 2,139 6,492,870 3,035 5,165 
2002 1,358 2,263 7,935,453 3,507 5,843 
2003 1,567 2,643 9,820,864 3,716 6,267 
2004 1,631 2,627 10,368,505 3,947 6,357 
2005 1,693 2,795 11,498,933 4,114 6,792 
2006 1,669 2,884 11,594,625 4,020 6,947 
2007 1,744 3,111 13,031,498 4,189 7,472 
2008 2,091 3,369 15,832,045 4,699 7,572 
2009 2,189 3,771 18,016,603 4,778 8,231 
2010 2,327 4,128 21,267,904 5,152 9,140 
2011 2,417 4,389 23,347,643 5,320 9,660 
2012 2,599 4,612 23,840,733 5,169 9,173 
2013 2,859 5,191 26,099,659 5,028 9,129 
2014 2,903 5,605 26,731,792 4,769 9,208 
2015 3,097 5,922 30,286,815 5,114 9,779 
Total - - 274,945,316 77,918 132,726 
 











The most common DED-associated comorbidities (Table 4) were related to hypertension 
in 31.7% of the cases, rheumatoid arthritis (15.7%), unspecified lipidemias and 
hyperlipidemias (10.4%), diabetes mellitus (10.1%) and atrial fibrillation (9.8%).  
Table 4 Dry eye disease-associated comorbidities  
ICD 9 code Disease description Visits (%) 
401.9 Essential hypertension, unspecified 19,666 (31.7%) 
714.0 Rheumatoid arthritis 9,771 (15.7%) 
272.4 
Other unspecified hyperlipidemias and 
lipidemias 
6,474 (10.4%) 
Hospitalizations    
 
Duration of stay in 
days (mean ± SD) 
9.6±11.6  
 Readmissions 8,430 13.6% 
Admission    
  Emergency 40,666 65.5% 
  Scheduled 21,205 34.2% 
  Other-unknown 179 0.3% 
Discharge    
  Home 57,338 92.4% 
  
Transfer to another 
Hospital  
1,176 1.9% 
  Voluntary  129 0.2% 
250.0 
Diabetes mellitus without mention of 
complication 
6,253 (10.1%) 
427.31 Atrial fibrillation 6,074 (9.8%) 
 
 
Total annual costs, mean costs per visit and mean cost per patient were calculated using 
the information provided within the hospital and health care centre database (Table 2). 
Mean costs per visit increase annually in a steady manner with slight oscillations and 
show a modest decrease from 2011 up to 2015 when the cost increments once again. 
Values range from 2,733.12€ (1997) to 5,114.29€ (2011) per visit. In regards to mean 
cost per patient, values are almost tripled within the 18 years of recorded data. The abrupt 
increase from 3,399.30€ in 1997 to 9,779.40€ in 2015 is also due to the increase of visits 
per patient.  
 
Taking this into account and the fact that a larger number of patients and visits are 
recorded, it is only expected that total cost of DED also grows annually, increasing more 
than 8 times over a period of 19 years. This escalates the total annual cost from 3.7M € in 
1997 to 30.3M € in 2015. 
5. DISCUSSION 
It is generally difficult to measure the number of cases of DED in the general population 
due to a series of aspects: first of all, the multifactorial nature of the disease but also 
scarce research and differential definitions of the disease, which the 2007 Report of the 
International Dry Eye Workshop (DEWS) attempted to address [4]. Additionally, 
according to the severity of the disease patients might opt to self-treat instead of visiting a 
health care centre and therefore are not accounted for in the databases.  
The results described in this article are within the scope of most past publications in 
regards to DED occurrence. Spanish DED number of cases calculated from 2006 to 2015 
are contained within the normal range and are in accordance with previous measurement 
regarding the north-western region of the country [8].  Results also agree with the fact 
that the disease is age-associated and more common in women.  
However literature regarding the cost of DED in France, Germany, Italy, Spain, Sweden 
and the United Kingdom suggest the disease has an occurrence of 0.03% in Spain [9]. 
Nevertheless, the value was calculated by means of the information provided by a survey 
addressed at consultant ophthalmologists who might have only treated the most severe 
cases of the disease. This particular study therefore excludes self-treated patients and 
patients treated by general practitioners and generalist ophthalmologists, which may 
explain the inconsistent results. 
The Salnes Eye Study in particular studied a total of 654 subjects from the north-western 
region of Spain, 37.2% of them males, with a mean age of 63.6 [SD 14.4] years, ranging 
from 40 to 96 [8]. In comparison, the present study accounts for 36081 patients from 
across the whole country, 11.94% of them males, with a similar age mean of 65.56 [SD 
15.24] ranging from 0 to 105 years.  
Whereas the 2009 Salnes Eye Study only found rosacea to be associated to DED, the 
2012 publication concerning symptomatic and asymptomatic MGD prevalence also 
describes diabetes and cardiovascular disease as the most common comorbidities for 
asymptomatic MGD and rosacea and rheumatoid arthritis in regards to symptomatic 
MGD. Our research agrees considering diabetes mellitus and rheumatoid arthritis as two 
of the most frequent comorbidities and adds hypertension, hyperlipidemias and 
lipidemias and atrial fibrillation to the list [11].  
Previously published data regarding DED-related annual costs is based on the 
information obtained from surveying ophthalmologists between the years 2003 and 2004. 
The 2009 report estimated the annual burden per patient for six European countries:  UK 
(approx. 1,100 USD), Spain (approx. 800 USD), Italy (approx. 600 USD), Germany 
(approx. 500 USD), Sweden (approx. 400 USD), and France (approx. 300 USD) [9]. 
A direct comparison is not feasible, however, considering the herein calculated mean 
costs per patient and per visit during the years 2003 and 2004, when data was collected 
for the Clegg et al. study, large discrepancies are observed. Values of 6,267.30 € in 2003 
and 6,357.15 € in 2004 per patient are obtained whereas a much lower cost is considered 
in the previous publication.  
This might be the case due to the use of very distinctive data acquisition methodologies: 
in one hand, acquired from healthcare records from hospitals and healthcare centres and 
on the other, based on ophthalmologist surveys.  
6. CONCLUSIONS 
The analysis of total hospitalisation records of DED in Spain indicates that DED-related 
hospitalisations entailed a mean cost per patient of 9,779.40€ in 2015.  
Estimated DED incidence is likely to increase due to the influence of modern day work 
place and lifestyle. For that reason, it is important to take into account the high economic 
burden and large decrease in QoL in regards to Spanish society and health policies.  
7. LIST OF ABBREVIATIONS 
DED: dry eye disease 
QoL: quality of life 
SS: Sjögren syndrome  
MGD: meibomian gland dysfunction 
ICD9: International statistical classification of diseases and related health problems, 9th 
revision 
SD: standard deviation 
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